Chunhua Yang

Dr. Chunhua Yang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JPJun Pan
Jun Pan
MDMeng Ding
Meng Ding
KXKai Xu
Kai Xu
CYChunhua Yang
Chunhua Yang
LMLi-Jun Mao
Li-Jun Mao
Oncotarget | https://doi.org/10.18632/oncotarget.18532 Jun Pan, Meng Ding, Kai Xu, Chunhua Yang, Li-Jun Mao Exosomes in diagnosis and therapy of prostate cancer

1 January 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HYHaiyuan Yu
Haiyuan Yu
JPJun Pan
Jun Pan
ZGZhicheng Guo
Zhicheng Guo
CYChunhua Yang
Chunhua Yang
LMLijun Mao
Lijun Mao
In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.

3 April 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LMLi-Jun Mao
Li-Jun Mao
YKYi Kan
Yi Kan
BLBing-Heng Li
Bing-Heng Li
SMSai Ma
Sai Ma
YLYirui Liu
Yirui Liu
CYChunhua Yang
Chunhua Yang
Prostate cancer is a common malignant tumor and the second leading cause of cancer-related death in men. Radiation therapy is a curative treatment for localized prostate cancer and has a limited effect for castration-resistant prostate cancer (CRPC). Interleukin 24 (IL-24) has a radiosensitizing effect in cancer cells. Our previous studies showed that ZD55-IL-24, an oncolytic adenovirus harboring IL-24, had better anti-tumor effect with no toxicity to normal cells. In this study, we evaluated the synergistic anti-tumor effect of oncolytic adenovirus ZD55-IL-24 combined with radiotherapy in prostate cancer. In Vitro and In Vivo experiments showed that the combined therapy significantly inhibited the growth of prostate cancer and provoked apoptosis of prostate cancer cells. In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.

28 October 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
KZKaichen Zhou
Kaichen Zhou
HLHaosen Lu
Haosen Lu
JZJielin Zhang
Jielin Zhang
QSQi Shen
Qi Shen
PLPengzhan Liu
Pengzhan Liu
LMLijun Mao
Lijun Mao
Prostate cancer is the most common malignant tumor in male genitourinary system. The incidence of prostate cancer ranks the first among all male malignant tumors worldwide, and the mortality rate ranks the second among all male malignant tumors. Prostate stem cells are heterogeneous subsets with the function of self-regeneration and proliferation in the prostate, which can produce all cell lineages that make up the prostate epithelium. At present, the pathogenesis of prostate cancer remains unclear. According to cancer stem cell hypothesis, prostate cancer may be a stem cell disease, which provides a new direction for revealing the pathogenesis of prostate cancer and developing treatment strategy for prostate cancer. In this mini-review, we highlight recent advances in our understanding of the origin, surface molecular markers, signaling pathway and the significance for clinical treatment of prostate cancer stem cells.

1 June 2019
Verified
Journal Article
Closed access
JLJihai Liu
Jihai Liu
YLYirui Liu
Yirui Liu
DYDongliang Yang
Dongliang Yang
CYChunhua Yang
Chunhua Yang
LMLijun Mao
Lijun Mao

22 December 2024 in Discover Oncology
Verified
Journal Article
Open access
QSQi Shen
Qi Shen
KZKaichen Zhou
Kaichen Zhou
HLHaosen Lu
Haosen Lu
JZJielin Zhang
Jielin Zhang
QXQiqing Xu
Qiqing Xu
LMLijun Mao
Lijun Mao
High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects of B7-H3 in tumors have been demonstrated, but the mechanism of B7-H3 immune response under dual effects is open to question. B7-H3 is crucially involved in the migration and invasion, angiogenesis, metabolism and chemotherapy resistance of prostate cancer. In addition to the potential immune effects on tumor environment, B7-H3 plays a non-immune-mediated role in tumor progression. In this review, we summarize current understanding of molecular mechanism of B7-H3 in prostate cancer and discuss the potential of B7-H3 as a novel therapeutic target for prostate cancer.